IP Group — Pfizer-Metsera deal offers upside potential
There have been several announcements on technical and commercial progress across IP Group’s portfolio this year. A recent highlight was Pfizer’s...
395 Views
IP Group — Exit target of over £250m by end-FY27 reiterated
IP Group continues to deliver a meaningful level of realisations with £30.3m in proceeds generated in H125, more than two-thirds of which came from...
251 Views
IP Group — Roadmap to value
IP Group made good progress in crystallising its portfolio values through exits, with proceeds of £183m collected in FY24, most notably from the...
317 Views
IP Group — Examining Istesso’s Phase IIb trial results
Istesso, IP Group’s largest private life sciences holding (c 11% of end-June 2024 portfolio value), has announced the results of its Phase IIb...
190 Views
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...
573 Views